Advancements in UTI Testing

A Multi-omics Approach to Maximizing the Flexibility of Your
Molecular Testing Laboratory



Wednesday, August 25, 2021 | 1-2 pm EDT

Sponsored By

Novel testing approaches enable clinical labs to advance and expand their UTI testing capabilities

While clinical microbiology laboratories are pivotal in the identification and handling of infectious diseases, the microbiology lab environment is rapidly changing. Conventional testing methods are being challenged as innovative testing methodologies emerge. Molecular testing is an ever-evolving world for the most common disease areas, including respiratory, urinary tract, and vaginal pathogen detection. In the case of testing for urinary tract infections (UTIs)—the second most common type of infection, with nearly half of positive UTI cases polymicrobial—current culture-based methods for detecting UTI pathogens have significant limitations. These include inability to address polymicrobial infections, long time to result, and false negatives due to poor sensitivity. Doubtful cases of UTI are of particular concern.

A molecular alternative that uses real-time PCR technology, however, has the potential to increase the specificity and sensitivity of pathogen detection. Additionally, advancements in UTI testing now include unique multi-omics approaches to detect bacterial interactions and address antibiotic resistance in polymicrobial samples.

Furthermore, while standard culture tests susceptibility on individual isolates, pooled antibiotic susceptibility testing (P-AST)—a unique method in which organisms are grouped together—takes into consideration bacterial interactions and may provide more effective therapy options.

Together, organism identification and antibiotic resistance gene detection through PCR testing coupled with P-AST provide an advanced solution backed by clinical evidence in effective diagnosis and treatment of polymicrobial UTIs.

With innovative testing methodologies now available to them, many clinical laboratories are assessing their current approaches to molecular testing or expanding their existing menu. They may be looking for solutions that can maximize resources and support flexibility, scale, expertise, and the lab’s unique needs. At the same time, in strategizing all services lines, labs are also challenged to realize significant cost savings, while ensuring the ability to evolve, respond, and adapt content, formats, and throughput to their communities’ needs.

The August 25 free webinar, Advancements in UTI Testing: A Multi-omics Approach to Maximizing the Flexibility of Your Molecular Testing Laboratory—sponsored by Thermo Fisher Scientific, in partnership with Pathnostics—will compare the clinical utility of genotypic and phenotypic methods in treatment of UTIs and describe how a multi-omics approach could be implemented in a laboratory.

Reserve your seat today to hear from experts speakers David Baunoch, PhD, Chief Scientific Officer and Co-Founder of Pathnostics, and Jorge Fonseca, MBA, Product Director of Genetic Testing Solutions, Genetic Sciences Division, Thermo Fisher Scientific.


Expert Panel

David Baunoch PhD Pathnostics crop sm

David Baunoch, PhD

Chief Scientific Officer and Co-Founder


David Baunoch received his PhD in microbiology and molecular genetics from Wayne State University and completed an NIH Postdoctoral Fellowship in Breast Cancer Research at the Michigan Cancer Foundation. Dr. Baunoch has more than 25 years of laboratory experience in a number of areas and has produced over 25 peer-reviewed publications. Before founding Pathnostics, he held a variety of executive management positions with industry-leading companies, including Ventana Medical Systems and US LABS, and was founder and president of Combimatrix Molecular Diagnostics.

Jorge Fonseca Thermo Fisher

Jorge Fonseca, MBA

Product Director, Genetic Testing Solutions, Genetic Sciences Division
Thermo Fisher Scientific

Jorge Fonseca holds a degree in Mechanical Engineering from the Massachusetts Institute of Technology and an MBA from the University of Massachusetts Amherst. He has 18 years of experience in the life sciences industry. Jorge started his career in R&D, where he was involved in the development of various qPCR-based products. Since transitioning to product management, he has held a number of roles with global ownership of product lines covering research, agrigenomics, and clinical applications. Currently, he leads a team responsible for a portfolio of molecular testing solutions spanning qPCR, capillary electrophoresis, and microarray technologies.

Learning Objectives

By attending Advancements in UTI Testing: A Multi-omics Approach to Maximizing the Flexibility of Your Molecular Testing Laboratory, you and your team will:

  • Understand the impact of urinary tract infections (UTIs) in patient care.
  • Evaluate the technical challenges and limitations associated with urine culture.
  • Explain the roles of the urinary microbiome and polymicrobial infections in the management of UTIs.
  • Compare the clinical utility of genotypic and phenotypic methods in treatment of UTIs.
  • Describe how a multi-omics approach could be implemented in a laboratory.
  • Learn how to implement molecular testing services or expand your existing menu.
  • Evolve content, formats, and throughput within a single platform for the most common disease areas including respiratory, urinary tract, and vaginal pathogen detection.
  • Explore controls and analytical validation service options needed for implementation.
Webinar image right

Who should attend?

  • Clinical laboratory directors
  • Laboratory managers
  • Clinical pathologists
  • Laboratory technicians
  • Academic medical centers
  • Public health laboratories
  • Anyone involved in clinical laboratory testing

Your registration includes:

  • The opportunity to pose specific questions and connect directly with speakers during a Q&A session
  • Access to the post-webinar recording

Hosted By

dark daily logo-no tags-FIT-white